Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
V205C, measles, mumps, and rubella virus vaccine live · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| V205C, measles, mumps, and rubella virus vaccine live | BIOLOGICAL | - |
| Comparator: Measles, Mumps, and Rubella Virus Vaccine Live | BIOLOGICAL | - |
Inclusion Criteria: * Healthy children 12 to 18 months of age. Exclusion Criteria: * Previous receipt of measles, mumps, rubella and/or varicella vaccine. * Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster. * Any medical condition that might in...
V205C is an investigational live vaccine developed by Merck & Company, Inc. (MRK) that targets measles, mumps, and rubella. It is being studied for the prevention of measles and is designed to prompt an immune response against these viruses. The vaccine is in Phase 2 clinical development.
V205C is being developed for the prevention of measles as part of a combined measles, mumps, and rubella vaccine. It is intended to protect against measles virus infection through active immunization. The asset is investigational and has been evaluated in a Phase 2 trial in healthy volunteers.
V205C is developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the clinical program evaluating this investigational measles, mumps, and rubella vaccine candidate.
V205C is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 2 program has been completed, with one completed trial and no active trials currently listed for this asset.
V205C has been evaluated in one completed Phase 2 trial, NCT00109278, titled A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010). The randomized, double-blind study enrolled 1,100 participants aged 12 months and older, including healthy volunteers, and has been completed.